Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James J Harding

Showing results (61-70 of 138) with videos related to

Pageof 14
Sort By:
Journal of the National Cancer Institute|December 14, 2025
NRG1 fusion-positive solid tumors: clinical detection, genomic landscape, and real-world data in pancreatic cancerAlison M Schram, Soo-Ryum Yang, Genessa Kahn, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association|April 28, 2019
Evolution of surgical management of gallbladder carcinoma and impact on outcome: results from two decades at a single-institutionJohn M Creasy, Debra A Goldman, Mithat Gonen, et al.
Cancers|October 29, 2025
Hepatocellular Carcinoma Growth Kinetics and Outcomes After Transarterial Embolization: A Single-Center AnalysisKen Zhao, Harrison Blume, Elena N Petre, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 20, 2021
CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of <sup>89</sup>Zr-Df-IAB22M2C, a Radiolabeled Anti-CD8 MinibodyMichael D Farwell, Raymond F Gamache, Hasan Babazada, et al.
Cancer Discovery|March 5, 2014
Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignanciesOmar Abdel-Wahab, Virginia M Klimek, Alisa A Gaskell, et al.
JCO Precision Oncology|September 11, 2020
<i>PTEN</i> Loss-of-Function Alterations Are Associated With Intrinsic Resistance to BRAF Inhibitors in Metastatic MelanomaFederica Catalanotti, Donavan T Cheng, Alexander N Shoushtari, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 31, 2019
A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced CancerJames J Harding, Andrew X Zhu, Todd M Bauer, et al.
JCO Precision Oncology|July 10, 2024
Extrahepatic Cholangiocarcinoma: Genomic Variables Associated With Anatomic Location and OutcomeWilliam A Preston, Esther Drill, Thomas Boerner, et al.
Cancer Research Communications|April 16, 2026
BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study FindingsJames J Harding, Ralf Hofheinz, Elena Élez, et al.
The Oncologist|May 10, 2015
A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain MetastasesJames J Harding, Federica Catalanotti, Rodrigo R Munhoz, et al.
Pageof 14

Showing results (61-70 of 138) with videos related to

Sort By:
Pageof 14
Journal of the National Cancer Institute|December 14, 2025
NRG1 fusion-positive solid tumors: clinical detection, genomic landscape, and real-world data in pancreatic cancerAlison M Schram, Soo-Ryum Yang, Genessa Kahn, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association|April 28, 2019
Evolution of surgical management of gallbladder carcinoma and impact on outcome: results from two decades at a single-institutionJohn M Creasy, Debra A Goldman, Mithat Gonen, et al.
Cancers|October 29, 2025
Hepatocellular Carcinoma Growth Kinetics and Outcomes After Transarterial Embolization: A Single-Center AnalysisKen Zhao, Harrison Blume, Elena N Petre, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 20, 2021
CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of <sup>89</sup>Zr-Df-IAB22M2C, a Radiolabeled Anti-CD8 MinibodyMichael D Farwell, Raymond F Gamache, Hasan Babazada, et al.
Cancer Discovery|March 5, 2014
Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignanciesOmar Abdel-Wahab, Virginia M Klimek, Alisa A Gaskell, et al.
JCO Precision Oncology|September 11, 2020
<i>PTEN</i> Loss-of-Function Alterations Are Associated With Intrinsic Resistance to BRAF Inhibitors in Metastatic MelanomaFederica Catalanotti, Donavan T Cheng, Alexander N Shoushtari, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 31, 2019
A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced CancerJames J Harding, Andrew X Zhu, Todd M Bauer, et al.
JCO Precision Oncology|July 10, 2024
Extrahepatic Cholangiocarcinoma: Genomic Variables Associated With Anatomic Location and OutcomeWilliam A Preston, Esther Drill, Thomas Boerner, et al.
Cancer Research Communications|April 16, 2026
BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study FindingsJames J Harding, Ralf Hofheinz, Elena Élez, et al.
The Oncologist|May 10, 2015
A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain MetastasesJames J Harding, Federica Catalanotti, Rodrigo R Munhoz, et al.
Pageof 14